Comparison of CD30L and OX40L Reveals CD30L as a Promising Therapeutic Target in Atopic Dermatitis. Gupta RK, Figueroa DS, Ay F, Causton B, et al. Allergy 2024 Nov 26. doi: 10.1111/all.16412.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Gupta RK, Figueroa DS, Ay F, Causton B, et al. Comparison of CD30L and OX40L Reveals CD30L as a Promising Therapeutic Target in Atopic Dermatitis. Allergy 2024 Nov 26. doi: 10.1111/all.16412.
PMID: 39589186